| Nov 17 |
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures
|
| Nov 13 |
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress
|
| Nov 12 |
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
|
| Nov 8 |
Ventyx Biosciences GAAP EPS of -$0.50
|
| Nov 7 |
Ventyx Biosciences files offering of common stock
|
| Nov 7 |
Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress
|
| Nov 4 |
Ventyx Biosciences: Ready To Escape "The Crash Cycle"
|
| Oct 29 |
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts
|
| Oct 15 |
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
|
| Sep 24 |
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
|
